Inhaled corticosteroids and risk of upper respiratory tract infection in patients with asthma: a meta-analysis
- 221 Downloads
Recent studies have suggested a possible association between respiratory infection and the use of inhaled corticosteroids (ICS). We aimed to ascertain the risk of upper respiratory tract infection (URTI) with long-term inhaled corticosteroid use among patients with asthma.
Through a comprehensive literature search of PubMed, Cochrane Library, EMBASE, and Google Scholar from inception to May 2018, we included randomized controlled trials of any ICS vs. a control treatment for asthma, with reporting of URTI as an adverse event. We conducted meta-analyses by the Peto approaches to generate summary estimates comparing ICS with non-ICS treatment on the risk of URTI.
Seventeen trials (15,336 subjects) were included. Compared with non-ICS treatment, ICSs were associated with a significantly increased risk of URTI (Peto OR, 1.24; 95% CI 1.08–1.42; I2 = 5%, p = 0.002). Subgroup analyses were performed for different dose, both high- and low-dose ICSs were associated with a significantly increased risk of URTI (high dose: Peto OR, 1.46; 95% CI 1.05–2.03; I2 = 0%; p = 0.03) (low dose: Peto OR, 1.20; 95% CI 1.04–1.39; I2 = 25%; p = 0.01). Moreover, fluticasone was observed with an increased risk of URTI (Peto OR, 1.18; 95% CI 1.02–1.38; p = 0.03; heterogeneity: I2 = 21%) but not budesonide, low-dose fluticasone treatment was associated with a significantly higher risk of URTI but not high dose.
This study raises safety concerns about the risk of URTI associated with ICS use in patients with asthma, but it should be further investigated.
KeywordsInhaled corticosteroids (ICS) Asthma Upper respiratory tract infection (URTI) Risk Meta-analysis
All authors contributed substantially to the study design, data analysis and interpretation, and the writing of the manuscript. The authors are indebted to all members of the Respiratory Diseases Laboratory of Chengdu Second People’s Hospital. Financial Support: Natural Science Foundation of China, Project Grant Numbers: 81650003. Chengdu Health Bureau Science and Technology Research Fund, Project Number: 20140735. Chengdu Science and Technology Project, Project Application Numbers: 2015-HM0100621-SF. The funding bodies had no role in the study design, manuscript writing, or decision to submit the manuscript for publication.
- 4.GlaxoSmithKline. GlaxoSmithKline clinical trials register. http://ctr.gsk.co.uk/medicinelist.asp. Accessed 26 Aug 2008.
- 10.Sheffer AL, Silverman M, Woolcock AJ, Díaz PV, Lindberg B, Lindmark B. Long-term safety of once-daily budesonide in patients with early-onset mild persistent asthma: results of the Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) study. Ann Allergy Asthma Immunol. 2005;94(1):48–54.CrossRefGoogle Scholar
- 11.Corren J, Korenblat PE, Miller CJ, O’Brien CD, Mezzanotte WS. Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. Clin Ther. 2007;29(5):823–43.CrossRefGoogle Scholar
- 14.Busse WW, Bleecker ER, Bateman ED, Lötvall J, Forth R, Davis AM, Jacques L, Haumann B, Woodcock A. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Thorax. 2012;67(1):35–41.CrossRefGoogle Scholar
- 16.Lin J, Tang H, Chen P, Wang H, Kim MK, Crawford J, Jacques L, Stone S. Efficacy and safety evaluation of once-daily fluticasone furoate/vilanterol in Asian patients with asthma uncontrolled on a low- to mid-strength inhaled corticosteroid or low-dose inhaled corticosteroid/long-acting beta2-agonist. Allergy Asthma Proc. 2016;37(4):302–10.CrossRefGoogle Scholar
- 17.Nathan RA, Rooklin A, Schoaf L, Scott C, Ellsworth A, House K, Dorinsky P. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study. Clin Ther. 2006;28(1):73–85.CrossRefGoogle Scholar
- 26.Lötvall J, Bleecker ER, Busse WW, O’Byrne PM, Woodcock A, Kerwin EM, Stone S, Forth R, Jacques L, Bateman ED. Efficacy and safety of fluticasone furoate 100 µg once-daily in patients with persistent asthma: a 24-week placebo and active-controlled randomised trial. Respir Med. 2014;108(1):41–9.CrossRefGoogle Scholar
- 29.Global Strategy for Asthma Management and Prevention. http://ginasthma.org/gina-reports/. Accessed May 2016.